Rebecca McLeod

Rebecca joined Scholar Rock in June 2025 as Chief Brand Officer and U.S. General Manager, overseeing Global Brand and Commercial Strategy. In this role, she will be responsible for leading the anticipated U.S. commercial launch of apitegromab for patients with spinal muscular atrophy (SMA) – along with establishing the global apitegromab brand strategy and market positioning for Europe, Asia-Pacific and Latin America. 

Previously, she served as U.S. General Manager at argenx, where she led market access, distribution, patient services, medical affairs, operations, marketing and sales for the U.S. organization. Under her leadership, argenx has delivered one of the most successful biopharmaceutical franchise launches with VYVGART. Rebecca has over two decades of biopharmaceutical industry experience, with much of her career focused on rare disease programs while serving in commercial leadership positions across sales, marketing and product management at Alexion Pharmaceuticals and Takeda Pharmaceuticals. 

Rebecca holds an M.B.A from The University of Arkansas at Little Rock and a B.A from the University of Mississippi.